Anthera Pharmaceuticals, Inc. (ANTH)

OTCMKTS: ANTH · Delayed Price · USD
0.0000
-0.0001 (-99.00%)
Jan 2, 2024, 3:32 PM EDT - Market closed

Company Description

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs.

It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy.

The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.

Anthera Pharmaceuticals, Inc.
Country United States
Founded 2004
IPO Date Mar 1, 2010
Industry Biotechnology
Sector Healthcare
Employees 21
CEO John Craig Thompson

Contact Details

Address:
25801 Industrial Boulevard, Suite B
Hayward, California 94545
United States
Phone (510) 856-5600
Website anthera.com

Stock Details

Ticker Symbol ANTH
Exchange OTCMKTS
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001316175
CUSIP Number 03674U300
ISIN Number US03674U3005
Employer ID 20-1852016
SIC Code 2834

Key Executives

Name Position
Paul F. Truex M.B.A. Executive Chairman
John Craig Thompson Chief Executive Officer and Director
May Liu Senior Vice President of Finance and Administration and Principal Accounting Officer
Dr. Paul Adams Ph.D. Senior Vice President of Global Regulatory Affairs and Compliance
Joshua Caldwell Chief Liquidating Officer

Latest SEC Filings

Date Type Title
Jul 30, 2018 15-12B Securities registration termination
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 26, 2018 EFFECT Notice of Effectiveness
Jul 20, 2018 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Jul 20, 2018 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments